Pharma Focus Asia
Klöckner Pentaplast - Pentapharm® alfoil® films

Talaris Therapeutics Develops Novel Cell Therapy FCR001 for the Treatment of Scleroderma

Novel cell therapy FCR001, was developed by Talaris for the treatment of patients with diffuse systemic sclerosis (SSc), a severe form of the rare autoimmune disease scleroderma.

Scleroderma, a rare and potentially fatal chronic autoimmune disease causes progressive scarring, or fibrosis, in the body’s connective tissues. Systemic scleroderma, also called systemic sclerosis (SSc) affects the skin and vital internal organs, especially the lungs, kidneys, gut and heart, resulting in organ dysfunction.

It is believed that FCR001 serve as a new treatment option for patients suffering with diffuse cutaneous systemic sclerosis, a subset of scleroderma with high morbidity and mortality. In addition, for individuals who need great need of safe and effective, disease-modifying, treatment, FCR001 would be the better option.

FCR001 is an investigational, allogeneic cell therapy developedto induce or restore patients’ immune tolerance.

Investigational New Drug (IND) FCR001has received both Orphan Drug Designation and Regenerative Medicine Advanced Therapy (RMAT) designation from the U.S. Food and Drug Administration.

magazine-slider-imageBIOVIA from Molecule to MedicineMFA + MMA 2024CPHI China || PMEC China 2024Asia Healthcare Week 2024Advance DoE WorkshopCPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinRehab Expo 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference3rd World ADC Asia 2024LogiPharma Asia 2024